{"id":2306,"date":"2019-12-31T19:32:10","date_gmt":"2019-12-31T18:32:10","guid":{"rendered":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/"},"modified":"2019-12-31T19:32:10","modified_gmt":"2019-12-31T18:32:10","slug":"evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener","status":"publish","type":"post","link":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/","title":{"rendered":"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH)."},"content":{"rendered":"<p><strong>2019<\/strong><\/p>\n<p><em>Mathias Vidon, St\u00e9phane Nahon<\/em><\/p>\n<p><strong>Gastroent\u00e9rologie <\/strong>&#8211; \u00a02019-05-20 &#8211;\u00a0CO &#8211;<\/p>\n<p>________________________________<\/p>\n<p>L\u2019ustekinumab est un inhibiteur des interleukines IL12\/23 qui a l\u2019autorisation de mise sur le march\u00e9 (AMM) dans le traitement du psoriasis depuis 2009, qui a \u00e9t\u00e9 \u00e9tendu au rhumatisme psoriasique.<br \/>\nCe traitement a obtenu l\u2019AMM en novembre 2016, dans la maladie de Crohn active mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re chez les patients adultes pr\u00e9sentant une r\u00e9ponse insuffisante, une perte de r\u00e9ponse ou une intol\u00e9rance \u00e0 un traitement conventionnel ou par anti-TNF\u03b1, ou qui pr\u00e9sentent une contre-indication m\u00e9dicale \u00e0 ces traitements.<br \/>\nCe traitement a fait preuve de son efficacit\u00e9 pour la maladie de Crohn, dans des \u00e9tudes de grande ampleur, chez des patients en \u00e9chec des anti-TNF, et plus r\u00e9cemment chez des patients na\u00effs, avec maintien de l\u2019efficacit\u00e9 dans le temps. Son \u00e9valuation dans la RCH est en cours.<br \/>\nEn cas de r\u00e9ponse insuffisante ou d\u2019inefficacit\u00e9, l\u2019attitude actuelle est de rapprocher le d\u00e9lai entre deux injections sous cutan\u00e9es \u00e0 4 semaines, au lieu du d\u00e9lai habituel (8 ou 12 semaines).<br \/>\nLe but de cette \u00e9tude est de d\u2019\u00e9valuer le nombre de patients ayant n\u00e9cessit\u00e9 une optimisation (rapprochement des injections) du traitement par Ustekinumab dans 2 centres hospitaliers g\u00e9n\u00e9raux de l\u2019ANGH.<\/p>\n<p>M\u00e9thodologie<br \/>\nEtude r\u00e9trospective, observationnelle incluant tous les patients adultes des services de gastro-ent\u00e9rologie du CHI Cr\u00e9teil et du CHI Le Raincy Montfermeil ayant b\u00e9n\u00e9fici\u00e9 d\u2019au moins une injection d\u2019Ustekinumab depuis 2015 (date de l\u2019ATU) pour une MICI.<br \/>\nL\u2019objectif principal est de d\u00e9terminer le pourcentage de patients ayant b\u00e9n\u00e9fici\u00e9 d\u2019une optimisation du traitement par ustekinumab.<br \/>\nR\u00e9sultats<br \/>\nAjaccio<\/p>\n","protected":false},"excerpt":{"rendered":"<p>2019 Mathias Vidon, St\u00e9phane Nahon Gastroent\u00e9rologie &#8211; \u00a02019-05-20 &#8211;\u00a0CO &#8211; ________________________________ L\u2019ustekinumab est un inhibiteur des interleukines IL12\/23 qui a l\u2019autorisation de mise sur le march\u00e9 (AMM) dans le traitement du psoriasis depuis 2009, qui a \u00e9t\u00e9 \u00e9tendu au rhumatisme psoriasique. Ce traitement a obtenu l\u2019AMM en novembre 2016, dans la maladie de Crohn active [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[30],"class_list":["post-2306","post","type-post","status-publish","format-standard","hentry","category-gastroenterologie","tag-30"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH). - Abstracts des congr\u00e8s de l&#039;ANGH<\/title>\n<meta name=\"description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH). - Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"og:description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/\" \/>\n<meta property=\"og:site_name\" content=\"Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-31T18:32:10+00:00\" \/>\n<meta name=\"author\" content=\"Bruno Lesgourgues\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bruno Lesgourgues\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/\"},\"author\":{\"name\":\"Bruno Lesgourgues\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/d70d83701c6dda5f93e12e8bafca7d7d\"},\"headline\":\"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH).\",\"datePublished\":\"2019-12-31T18:32:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/\"},\"wordCount\":329,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"keywords\":[\"2019\"],\"articleSection\":[\"Gastroenterologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/\",\"url\":\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/\",\"name\":\"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH). - Abstracts des congr\u00e8s de l&#039;ANGH\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#website\"},\"datePublished\":\"2019-12-31T18:32:10+00:00\",\"description\":\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\",\"breadcrumb\":{\"@id\":\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/angh.net\/abstracts\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH).\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/angh.net\/abstracts\/#website\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"name\":\"Abstracts des congr\u00e8s de l&#039;ANGH\",\"description\":\"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003\",\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/angh.net\/abstracts\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\",\"name\":\"ANGH\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"contentUrl\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"width\":48,\"height\":18,\"caption\":\"ANGH\"},\"image\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/d70d83701c6dda5f93e12e8bafca7d7d\",\"name\":\"Bruno Lesgourgues\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/5c737979cf1cff53a280fef17e77a5e495d143e87a53eee6fcc0b272bb973c75?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5c737979cf1cff53a280fef17e77a5e495d143e87a53eee6fcc0b272bb973c75?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5c737979cf1cff53a280fef17e77a5e495d143e87a53eee6fcc0b272bb973c75?s=96&d=mm&r=g\",\"caption\":\"Bruno Lesgourgues\"},\"url\":\"https:\/\/angh.net\/abstracts\/author\/blesgourgues-2\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH). - Abstracts des congr\u00e8s de l&#039;ANGH","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/","og_locale":"fr_FR","og_type":"article","og_title":"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH). - Abstracts des congr\u00e8s de l&#039;ANGH","og_description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","og_url":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/","og_site_name":"Abstracts des congr\u00e8s de l&#039;ANGH","article_publisher":"https:\/\/www.facebook.com\/ANGH-2136322560030484\/","article_published_time":"2019-12-31T18:32:10+00:00","author":"Bruno Lesgourgues","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Bruno Lesgourgues","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/#article","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/"},"author":{"name":"Bruno Lesgourgues","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/d70d83701c6dda5f93e12e8bafca7d7d"},"headline":"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH).","datePublished":"2019-12-31T18:32:10+00:00","mainEntityOfPage":{"@id":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/"},"wordCount":329,"commentCount":0,"publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"keywords":["2019"],"articleSection":["Gastroenterologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/","url":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/","name":"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH). - Abstracts des congr\u00e8s de l&#039;ANGH","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/#website"},"datePublished":"2019-12-31T18:32:10+00:00","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","breadcrumb":{"@id":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/angh.net\/abstracts\/evaluation-du-taux-doptimisation-du-traitement-par-ustekinumab-chez-des-patients-porteurs-dune-maladie-inflammatoire-chronique-intestinale-mici-dans-deux-centres-hospitaliers-gener\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/angh.net\/abstracts\/"},{"@type":"ListItem","position":2,"name":"Evaluation du taux d\u2019optimisation du traitement par Ustekinumab chez des patients porteurs d\u2019une maladie inflammatoire chronique intestinale (MICI) dans deux centres hospitaliers g\u00e9n\u00e9raux de l\u2019Association nationale des h\u00e9pato-gastro-ent\u00e9rologues des h\u00f4pitaux g\u00e9n\u00e9raux (ANGH)."}]},{"@type":"WebSite","@id":"https:\/\/angh.net\/abstracts\/#website","url":"https:\/\/angh.net\/abstracts\/","name":"Abstracts des congr\u00e8s de l&#039;ANGH","description":"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003","publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angh.net\/abstracts\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/angh.net\/abstracts\/#organization","name":"ANGH","url":"https:\/\/angh.net\/abstracts\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/","url":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","contentUrl":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","width":48,"height":18,"caption":"ANGH"},"image":{"@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ANGH-2136322560030484\/"]},{"@type":"Person","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/d70d83701c6dda5f93e12e8bafca7d7d","name":"Bruno Lesgourgues","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/5c737979cf1cff53a280fef17e77a5e495d143e87a53eee6fcc0b272bb973c75?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5c737979cf1cff53a280fef17e77a5e495d143e87a53eee6fcc0b272bb973c75?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5c737979cf1cff53a280fef17e77a5e495d143e87a53eee6fcc0b272bb973c75?s=96&d=mm&r=g","caption":"Bruno Lesgourgues"},"url":"https:\/\/angh.net\/abstracts\/author\/blesgourgues-2\/"}]}},"_links":{"self":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/2306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/comments?post=2306"}],"version-history":[{"count":0,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/2306\/revisions"}],"wp:attachment":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/media?parent=2306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/categories?post=2306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/tags?post=2306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}